Longeveron
在场
Longeveron 是一家在股票代码 LGVN (US) 下上市的公司。
高管
查看带有其 16 名主要高管的组织结构图
Longeveron 搜索最多的简介
高管在Longeveron变化
- Roger Hajjar已作为Director加入公司 (新闻发布的2024七月9号).
- Cathy Ross, Director, 已经离开公司 (新闻发布的2024五月13号).
- Jeffrey Pfeffer, Director, 已经离开公司 (新闻发布的2024五月13号).
创建提醒
跟踪 Longeveron 的高管变动
生物技术
Longeveron 拥有 2,317 家竞争者，其中包括 Eurofins (卢森堡)、Lonza (瑞士) 和 Biogen (美国(美洲))。
Popular M&A news in 生物技术
- Evommune 刚刚宣布为 115 筹款数百万美元。 (公布2024十一月4号).
- AgomAb Therapeutics 刚刚宣布为 89 筹款数百万美元。 (公布2024十月29号).
- Seaport Therapeutics 刚刚宣布为 225 筹款数百万美元。 (公布2024十月25号).
生物技术 行业的其他推荐联系人
消息
Longeveron 的最新新闻稿
- Longeveron® Presents Lomecel-B™ Data for Alzheimer’s Disease Indication in Late Breaking Poster Presentation at the Clinical Trials on Alzheimer’s Disease Conference (CTAD24)
- Longeveron® Presents Lomecel-B™ Long-term Transplant-free Survival Data in Hypoplastic Left Heart Syndrome (HLHS) at the Congenital Heart Surgeons’ Society (CHSS) 51st Annual Meeting
- Longeveron® Lomecel-B™ Data in Alzheimer’s Disease Selected for Late Breaking Poster Presentation at the Clinical Trials on Alzheimer’s Disease Conference (CTAD24)
- Longeveron® to Present at the UBS Virtual Organ Restoration and Cell Therapy Day
- Longeveron® Lomecel-B™ 5-Year Long-term Transplant-free Survival Data in HLHS Selected for Oral Presentation at the Congenital Heart Surgeons’ Society (CHSS) 51st Annual Meeting
- Longeveron® to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference
- Longeveron to Attend Alliance for Regenerative Medicine’s Cell & Gene Meeting on the Mesa
- Longeveron to Present at the H.C. Wainwright 26th Annual Global Investment Conference
- Longeveron® Announces U.S. FDA Grants Lomecel-B™ Regenerative Medicine Advanced Therapy (RMAT) Designation for the Treatment of Mild Alzheimer’s Disease
- Longeveron® to Attend BIO International Convention 2024
- View more press releases Close
关于 Longeveron 的社交媒体
保持联系
通过电子邮件联系联系该企业高管，包括 Wa'el Hashad 
